Technetium Therapeutics

AI-driven hatchery of novel medicines

- The Founders
- Re-inventing the Process How Drugs Are Invented
- Our Platform: AI Drug Design, DRUG-seq and Lab Automation
- Our Pipelines, Clinical Differentiation Strategy and Business Strategy

We Are Domain and AI Experts

Technetium Therapeutics
AI-driven hatchery of novel medicines

Cheng Hu

Co-Founder, CEO

- Director of medicinal chemistry and team lead for over 10 drug discovery projects
- Co-lead of Atomwise AI model development to support drug discovery projects

Chunlin Wang

Co-Founder, CTO

- Founder of several successful companies in the biotech industries
- Inventor of several innovative algorithms that have become industry standards

Technetium Therapeutics founders are biotech industry veterans who are at the forefront of AI applications

Invent Novel Medicines, Much Faster

Technetium Therapeutics
AI-driven hatchery of novel medicines

AI-driven Design

Our proprietary AI Agentic Workflow generates novel chemotypes, enabling the development of innovative drugs with superior clinical performance



Drug-Seq

By integrating Drug-Seq into the drug development process, we can optimize drug candidates, reduce costs, and improve the success rates of novel medicines

Automation

Incorporating automation into the drug development process, particularly in lead optimization, can significantly accelerate drug development

Technetium Therapeutics is leveraging AI-driven drug design, DRUG-seq and automation to develop novel medicines

Traditional Drug Screening Process

Technetium Therapeutics
AI-driven hatchery of novel medicines



Hit Screening and Optimization	18-24 Months	$2-3 millions
Lead Optimization	12-18 Months	$2-3 millions
Candidate Selection	12 months	$2-3 millions
IND Enabling	12 months	$2-3 millions

Developing one clinical candidate with traditional process typically costs $10 million and takes 4 to 5 years

Our AI-Driven Drug Design Process

Technetium Therapeutics
AI-driven hatchery of novel medicines

Lead Design and Validation	8-12 weeks	$30-50K
Lead Optimization (PCT Filing）	12-16 weeks	$100-200K
Candidate Selection	6-9 months	$1-2 millions
IND Enabling	6-9 Month	$2-3 millions

AI-driven drug design reduces both cost and time of drug development by more than 50%

Our AI Agentic Lead Design Workflow

Technetium Therapeutics
AI-driven hatchery of novel medicines



- Our structure generation agent (trained by ChEMBL dataset) and PLI review agent(trained by SAIR dataset) operate in tandem to generate drug-like small molecules on biological targets in scale.
- Running iterations can solve complex problems one step at a time
- Human expertise provides a guardrail in each round of iteration

We are developing a proprietary AI-driven agentic workflow to discover novel leads

Explainable, Trainable Synthetic Data in Scale

Technetium Therapeutics
AI-driven hatchery of novel medicines

Other GenerativeAIs start with know ligands, generate inexplainable results



Nature Communications Chemistry | (2025) 8:238

Our GenerativeAI starts with protein, generates results with explainable physics



tc-43.ai, Project 9:KRAS

- Our generated ligands are highly complementary to the binding pocket/PPI surface (Vina docking score <-12 kcal/mol)
- The ligand generation process is explainable in the context of target protein/PPI
- The generated ligands are synthesizable

The synthetic dataset we generated are rich in machine labeled information, which can be used to train in-house AI models for drug discovery

Validation of Our Design Platform

Technetium Therapeutics
AI-driven hatchery of novel medicines

	TCTX Lead	Approved Drug
CNS Penetrant c-Abl inhibitor (Patent pending)		
Gut-restricted TYK2 inhibitor (Patent pending)		
CNS Penetrant EGFR mutants inhibitor		

Our platform has demonstrated the capability to design novel, lead-like compounds with measured high potency

Collaboration Opportunities

Technetium Therapeutics
AI-driven hatchery of novel medicines

Who can benefit from our synthetic data

- ❑ Biotech and Pharma companies developing novel therapeutics
- ❑ AI drug discovery platforms accelerating scientific discovery and drug discovery
- ❑ Large quantitative model AI platforms

Our high-quality, machine-labeled synthetic data fuels therapeutic discovery and large quantitative model training

Our Pipelines

Technetium Therapeutics
AI-driven hatchery of novel medicines

Our Internal Drug Discovery Projects

- ❑ Gut-restricted TYK2 inhibitors for IBD (in vivo validation)
- ❑ CNS penetrant c-Abl inhibitors for neuron degenerative diseases (in vivo validation)
- ❑ CNS penetrant GLP agonist for neurodegenerative diseases (Lead Generation)

Our pipelines at Technetium Therapeutics center on key immunology, CNS and oncology diseases

Our AIDD Labs (Under Construction)

Technetium Therapeutics
AI-driven hatchery of novel medicines



- The high throughput, high dimension and high-quality DRUG-seq data generated from our AIDD Labs will accelerate the development of novel medicines
- Fast iteration leads to greater efficiency and superior models
- Our AI labs automate synthesis and assays, slashing iteration time by over 70%

The combination of our AI Labs and AI Design capabilities can significantly improve lead optimization efficiency

2025-2026 Finance and Business Plan

Technetium Therapeutics
AI-driven hatchery of novel medicines

Non-dilutive funding - $700,000: build AI-Labs and high throughput genomic profiling labs

Team Building: Expanding our team to 8-10 employees to productionize AI agentic workflows and optimize lead operations

Equity investments - $10-15 million: Scaling to 10 lead optimization projects, among them 2 clinical development candidate will be nominated

Efficient capital deployment is crucial for creating a productive hatchery of novel medicines

Our Current Facility

Technetium Therapeutics
AI-driven hatchery of novel medicines









Menlo Park, our home, is the epicenter of the AI revolution and drug discovery breakthroughs

